Table.
Estimated survival percentages and absolute benefits of streptokinase both overall and in patient subgroups during days 0-35 and day 0 to year 4
| No of patients randomised
|
Follow up in days 0-35
|
Follow up in day 0 to year 4
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Survival (%)
|
Absolute benefit (CI*) per 1000 patients | Survival (%)
|
Absolute benefit (CI*) per 1000 patients | |||||||
| Category of patient at entry to study | SK | Placebo | SK | Placebo | SK | Placebo | ||||
| Hours from onset: | ||||||||||
| 0-3 | 2551 | 2557 | 91.8 | 87.5 | 43 (21 to 65) | 77.7 | 73.0 | 48 (15 to 80) | ||
| 4-6 | 2799 | 2803 | 90.4 | 87.8 | 26 (4 to 47) | 73.8 | 72.2 | 16 (−16 to 48) | ||
| 7-12 | 2018 | 2008 | 89.4 | 87.4 | 19 (−7 to 45) | 72.8 | 70.4 | 24 (−15 to 62) | ||
| 13-24 | 1224 | 1227 | 91.3 | 89.0 | 23 (−8 to 54) | 74.2 | 72.2 | 20 (−29 to 69) | ||
| Age (years): | ||||||||||
| <70 | 6949 | 6910 | 93.0 | 90.2 | 27 (15 to 40) | 79.9 | 77.5 | 23 (4 to 42) | ||
| ⩾70 | 1643 | 1685 | 81.0 | 77.7 | 33 (−3 to 69) | 53.1 | 49.0 | 41 (−7 to 89) | ||
| Sex: | ||||||||||
| Male | 6522 | 6612 | 92.0 | 88.9 | 31 (18 to 44) | 76.3 | 73.2 | 31 (10 to 51) | ||
| Female | 2023 | 1930 | 86.6 | 84.2 | 24 (−5 to 53) | 70.3 | 68.2 | 21 (−18 to 60) | ||
| Pre-randomisation ECG: | ||||||||||
| Bundle branch block | 373 | 385 | 79.3 | 74.8 | 45 (−33 to 124) | 55.0 | 52.3 | 27 (−70 to 124) | ||
| Anterior ST elevation† | 2067 | 2056 | 89.1 | 81.8 | 73 (44 to 101) | 72.0 | 65.8 | 62 (24 to 101) | ||
| Inferior ST elevation | 2128 | 2152 | 92.5 | 90.9 | 15 (−6 to 37) | 78.2 | 76.1 | 21 (−13 to 56) | ||
| ST depression | 610 | 605 | 81.3 | 82.4 | −11 (−68 to 46) | 61.6 | 60.8 | 9 (−66 to 83) | ||
| Other‡ | 2398 | 2288 | 95.4 | 93.8 | 16 (−1 to 33) | 81.7 | 79.4 | 22 (−9 to 54) | ||
| Diabetes: | ||||||||||
| Yes | 620 | 669 | 87.9 | 82.5 | 54 (3 to 105) | 62.0 | 59.3 | 27 (−49 to 102) | ||
| No | 7880 | 7832 | 91.0 | 88.3 | 26 (14 to 39) | 75.9 | 73.2 | 27 (9 to 46) | ||
| Previous myocardial infarction: | ||||||||||
| Yes | 1497 | 1442 | 87.0 | 82.7 | 43 (9 to 77) | 59.7 | 57.8 | 18 (−30 to 67) | ||
| No | 7003 | 7059 | 91.6 | 88.9 | 26 (13 to 39) | 78.2 | 75.1 | 32 (12 to 51) | ||
| Treatment comparisons: | ||||||||||
| SK plus aspirin v aspirin alone | 4292 | 4295 | 91.9 | 89.2 | 27 (11 to 44) | 75.7 | 73.3 | 24 (−1 to 49) | ||
| SK alone v double placebo | 4300 | 4300 | 89.5 | 86.4 | 31 (13 to 49) | 73.9 | 70.7 | 32 (6 to 58) | ||
| Overall | 8592 | 8595 | 90.7 | 87.8 | 29 (20 to 38) | 74.8 | 72.0 | 28 (14 to 42) | ||
SK=streptokinase, ECG=electrocardiogram.
*
95% confidence intervals given for overall absolute benefits at day 35 and end of year 4, and 99% confidence intervals for absolute benefits in subgroups of patients.
†
Includes 164 streptokinase patients and 152 placebo patients who also had inferior ST elevation.
‡
Includes some patients with normal electrocardiograms.